Dr. Reddy's Laboratories and its subsidiary CRDMO Aurigene Pharmaceutical Services have signed a non-binding memorandum of understanding with the US-based firm Kainomyx for the development and commercialization of anti-malarial drugs in the US, Europe and low and middle-income countries.
Dr Reddy’s Teams Up With Kainomyx For Anti-Malarial Drug Development
Dr Reddy’s Subsidiary Aurigene Will Handle Drug Chemistry
Marking another step in Dr Reddy’s diverse corporate strategy, the company has signed a memorandum of understanding with Kainomyx for the development and commercialization of anti-malarials in multiple markets.
